Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 132.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,560,410 shares of the biopharmaceutical company's stock after buying an additional 889,968 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.52% of Amicus Therapeutics worth $14,699,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Covestor Ltd raised its stake in shares of Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 2,312 shares during the last quarter. R Squared Ltd acquired a new position in Amicus Therapeutics in the fourth quarter valued at about $79,000. KBC Group NV increased its stake in Amicus Therapeutics by 44.4% during the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after purchasing an additional 3,120 shares in the last quarter. Sciencast Management LP bought a new stake in Amicus Therapeutics during the 4th quarter worth about $100,000. Finally, Stephens Inc. AR acquired a new position in Amicus Therapeutics during the fourth quarter worth approximately $101,000.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD traded down $0.12 during trading hours on Monday, reaching $6.32. The company had a trading volume of 1,660,570 shares, compared to its average volume of 2,807,976. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. The business's 50 day moving average price is $7.37 and its 200-day moving average price is $8.88. Amicus Therapeutics, Inc. has a 1-year low of $5.81 and a 1-year high of $12.65. The firm has a market cap of $1.94 billion, a PE ratio of -35.07, a price-to-earnings-growth ratio of 1.51 and a beta of 0.64.

Analyst Ratings Changes

A number of equities analysts have issued reports on FOLD shares. Wells Fargo & Company lowered their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. UBS Group increased their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research note on Thursday, February 20th. StockNews.com lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, The Goldman Sachs Group decreased their price target on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.22.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.